MedTrace Logo

Non-Invasive Screening for Fetal Aneuploidy

NCT00847990 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2011-09-05

No results posted yet for this study

Summary

The purpose of this study is to determine if a laboratory test developed by the Sequenom Center for Molecular Medicine (SCMM) that uses a new marker found in the mother's blood can better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), or other chromosome abnormality.

Conditions

  • Down Syndrome
  • Edwards Syndrome

Interventions

OTHER

Maternal blood screening test for fetal aneuploidy

One blood draw of 20 to 30 mL

Sponsors & Collaborators

  • Obstetrix

    collaborator UNKNOWN

  • Sequenom, Inc.

    lead INDUSTRY

Principal Investigators

  • Richard Porreco, MD · Obstetrix Medical Group of Colorado

  • Thomas J Garite, MD · Obstetrix

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2011-04-30
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00847990 on ClinicalTrials.gov